DBVT News and Press, DBV Technologies S.A. From 12/22/21

BiondVax Pharmaceuticals (NASDAQ:BVXV) +55% signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany. BioRestorative Therapi...

Gainers: Reliance Global Group (NASDAQ:RELI) +89%. Biofrontera  (NASDAQ:BFRI) +49%. IsoPlexis Corporation (NASDAQ:ISO) +37%. Chemomab Therapeutics  (NASDAQ:CMMB) +29%. iSpecimen  (NASDAQ:ISPC) +28%. Aldeyra Therapeutics (NASDAQ:ALDX) -51%. DBV Technologies&#...

Gainers: Reliance Global Group (NASDAQ:RELI) +82%. Biofrontera (NASDAQ:BFRI) +49%. Jaguar Health (NASDAQ:JAGX) +43%. IsoPlexis (NASDAQ:ISO) +31%. Aridis Pharmaceuticals (NASDAQ:ARDS) +28%. Petros Pharmaceuticals (NASDAQ:PTPI) +30%. Eqonex (NASDAQ:EQOS) +26%. Quantum-Si incorporated (NASDAQ:QS...

Shares of DBV Technologies (NASDAQ: DBVT) , a clinical-stage biopharmaceutical company, took a sharp turn for the worse today. Investors reacting to disappointing news about the development of Viaskin Peanut, its treatment for those with peanut allergies, pushed the stock 37.8% lowe...

DBV Technologies (DBVT -41.1%) ADRs have lost sharply after the company announced its plans to begin a new Phase 3 pivotal trial for the modified Viaskin Peanut patch. The study for the intended patient population will be designed to evaluate the modified Viaskin Peanut (mVP) patch, which is ...

Gainers: uCloudlink Group  (NASDAQ:UCL) +15%. Quantum-Si Incorporated QSI +10%. Micron Technology  MU +7%. Braze BRZE +6%. JAKKS Pacific (NASDAQ:JAKK) +6%. Losers: CytomX Therapeutics CTMX -29%. DBV Technologies  (NASDAQ:DBVT) -13%. Sigilon Therape...

Montrouge, France, December 20, 2021 DBV Technologies Provides Update on Investigational Viaskin ™ Peanu t DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, tod...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris...

Montrouge, France, November 24, 2021 DBV Technologies to Participate in an Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation ...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris IS...